CY1107383T1 - Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος - Google Patents

Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος

Info

Publication number
CY1107383T1
CY1107383T1 CY20081100371T CY081100371T CY1107383T1 CY 1107383 T1 CY1107383 T1 CY 1107383T1 CY 20081100371 T CY20081100371 T CY 20081100371T CY 081100371 T CY081100371 T CY 081100371T CY 1107383 T1 CY1107383 T1 CY 1107383T1
Authority
CY
Cyprus
Prior art keywords
physology
suspensions
solution
enzymes
compounds
Prior art date
Application number
CY20081100371T
Other languages
English (en)
Inventor
John Caedmon Mckew
Steve Yik-Kai Tam
James Donald Clark
Katherine Lin Lee
Lihren Chen
Paresh Thakker
Fuk-Wah Sum
Mark Leo Behnke
Baihua Hu
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of CY1107383T1 publication Critical patent/CY1107383T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

Η εφεύρεση αυτή παρέχει ενώσεις υποκατεστημένου ινδολίου του γενικού τύπου (I) και φαρμακευτικώς αποδεκτές μορφές άλατος αυτών και μεθόδους για χρήση των ενώσεων ως αναστολέων της δραστικότητας διαφόρων ενζύμων φωσφολιπάσης, ιδιαιτέρως ενζύμων φωσφολιπάσης Α2 και για την ιατρική θεραπεία, πρόληψη και αναστολή πόνου και φλεγμονής.
CY20081100371T 2001-12-03 2008-03-31 Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος CY1107383T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33458801P 2001-12-03 2001-12-03
US33459101P 2001-12-03 2001-12-03
US33460501P 2001-12-03 2001-12-03
US41966402P 2002-10-18 2002-10-18
EP02786829A EP1451154B1 (en) 2001-12-03 2002-12-02 Inhibitors of cytosolic phospholipase a2

Publications (1)

Publication Number Publication Date
CY1107383T1 true CY1107383T1 (el) 2012-12-19

Family

ID=27502498

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100371T CY1107383T1 (el) 2001-12-03 2008-03-31 Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος

Country Status (25)

Country Link
EP (1) EP1451154B1 (el)
JP (1) JP4657605B2 (el)
KR (1) KR100973665B1 (el)
CN (1) CN100503566C (el)
AR (1) AR037684A1 (el)
AT (1) ATE384045T1 (el)
AU (1) AU2002351182B2 (el)
BR (1) BR0214672A (el)
CA (1) CA2469138C (el)
CO (1) CO5580763A2 (el)
CY (1) CY1107383T1 (el)
DE (1) DE60224707T2 (el)
DK (2) DK1451154T3 (el)
EC (1) ECSP045131A (el)
ES (2) ES2401454T3 (el)
HK (2) HK1065799A1 (el)
HU (1) HUP0402577A3 (el)
IL (2) IL162052A0 (el)
IN (1) IN2005KO00312A (el)
NO (1) NO327256B1 (el)
NZ (1) NZ533269A (el)
PL (1) PL370445A1 (el)
PT (1) PT1451154E (el)
TW (1) TWI334778B (el)
WO (1) WO2003048122A2 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7253291B2 (en) 2003-11-17 2007-08-07 Wyeth Processes for the preparation of N-substituted phthalimides
HN2004000536A (es) * 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AR048239A1 (es) 2004-02-25 2006-04-12 Wyeth Corp Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo e intermediarios de sintesis de los mismos
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
PL1719507T3 (pl) 2005-04-13 2010-12-31 Cipher Pharmaceuticals Inc Agoniści receptora beta2-adrenergicznego do leczenia chorób tkanki łącznej skóry
GT200600228A (es) 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
NI200800018A (es) * 2005-07-21 2009-03-03 Procedimiento para la síntesis de haluros de sulfonilo y sulfonamidas a partir de sales de ácido sulfónico .
JP2009514893A (ja) 2005-11-03 2009-04-09 イリプサ， インコーポレイテッド 多価インドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
FR2899471A1 (fr) * 2006-04-06 2007-10-12 Pasteur Institut Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme medicament pour le traitement des maladies respiratoires
US20080009485A1 (en) * 2006-05-26 2008-01-10 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
TW200829549A (en) * 2006-10-31 2008-07-16 Wyeth Corp Liquid formulations of phospholipase enzyme inhibitors
WO2008055146A2 (en) * 2006-10-31 2008-05-08 Wyeth Formulations of phospholipase enzyme inhibitors
RU2009139931A (ru) * 2007-03-29 2011-05-10 Асубио Фарма Ко., Лтд. (Jp) Производные индола, обладающие ингибирующей активностью в отношении сpla2, и способы их получения
KR101269393B1 (ko) 2008-04-28 2013-05-29 아사히 가세이 파마 가부시키가이샤 페닐프로피온산 유도체 및 이의 용도
AU2010306750B2 (en) * 2009-10-15 2014-11-13 Children's Medical Center Corporation Sepiapterin reductase inhibitors for the treatment of pain
WO2012031763A1 (en) 2010-09-08 2012-03-15 Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079374C (en) * 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
CN1310706A (zh) * 1998-02-25 2001-08-29 遗传研究所有限公司 磷脂酶抑制剂
IL137718A0 (en) * 1998-02-25 2001-10-31 Genetics Inst Inhibitors of phospholipase enzymes

Also Published As

Publication number Publication date
KR100973665B1 (ko) 2010-08-04
AU2002351182B2 (en) 2009-01-15
EP1451154B1 (en) 2008-01-16
HUP0402577A2 (hu) 2005-03-29
ES2300490T3 (es) 2008-06-16
DE60224707T2 (de) 2009-02-26
HK1113798A1 (en) 2008-10-17
ATE384045T1 (de) 2008-02-15
DK1892239T3 (da) 2013-03-25
ECSP045131A (es) 2004-07-23
HK1065799A1 (en) 2005-03-04
DK1451154T3 (da) 2008-05-19
NO20042679L (no) 2004-06-25
WO2003048122A2 (en) 2003-06-12
PL370445A1 (en) 2005-05-30
JP4657605B2 (ja) 2011-03-23
TW200301695A (en) 2003-07-16
TWI334778B (en) 2010-12-21
CN1617855A (zh) 2005-05-18
PT1451154E (pt) 2008-04-21
KR20050044661A (ko) 2005-05-12
CN100503566C (zh) 2009-06-24
IL162052A0 (en) 2005-11-20
CA2469138C (en) 2012-04-17
BR0214672A (pt) 2004-10-19
NO327256B1 (no) 2009-05-25
EP1451154A2 (en) 2004-09-01
AR037684A1 (es) 2004-12-01
IL162052A (en) 2013-04-30
NZ533269A (en) 2006-03-31
JP2005515997A (ja) 2005-06-02
CA2469138A1 (en) 2003-06-12
IN2005KO00312A (el) 2015-08-14
WO2003048122A3 (en) 2003-09-18
ES2401454T3 (es) 2013-04-19
AU2002351182A1 (en) 2003-06-17
DE60224707D1 (de) 2008-03-06
HUP0402577A3 (en) 2011-05-30
CO5580763A2 (es) 2005-11-30

Similar Documents

Publication Publication Date Title
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
ATE408601T1 (de) Fredericamycin-derivate
EA200400073A1 (ru) Пирролопиримидины как ингибиторы протеинкиназы
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
CY1115891T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
CY1110171T1 (el) Ιατρικη χρηση αναστολεων γλουταμινικων και γλουταμικων κυκλασων για θεραπεια της ασθενειας του alzheimer και του συνδρομου down
CY1108813T1 (el) Αναστολεις κινασων τυροσινης
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
CY1107069T1 (el) Χρηση των αναστολεων της cox-2 σαν ανοσοδιεγερτες στη θεραπεια του hiv ή του aids
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
SE0101932D0 (sv) Pharmaceutical combinations
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
BR0213994A (pt) Derivados heterocìclicos de glicinamida e seus usos médicos
CY1110415T1 (el) Πρωτοτυπα παραγωγα τετραϋδροκαρβαζολιου με βελτιωμενη βιολογικη δραση και βελτιωμενη διαλυτοτητα, ως συνδετες για υποδοχεις συζευγμενους με πρωτεϊνη g (gpcrs)
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
PA8466101A1 (es) Agentes terapeuticos